ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
0,00%
Dow Jones
39 872,99
0,17%
DAX
18 726,76
-0,21%
Brent Oil
82,125
-0,39%
Bitcoin
69 851,18
-0,40%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) Actualités

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BEAM
DateHeureSourceTitreSymboleSociété
14/05/202422h00GlobeNewswire Inc.Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:BEAMBeam Therapeutics Inc
08/05/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
07/05/202413h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
07/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
07/05/202412h30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
26/03/202411h30GlobeNewswire Inc.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
28/02/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413h40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BEAMBeam Therapeutics Inc
27/02/202412h30GlobeNewswire Inc.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
05/02/202412h30GlobeNewswire Inc.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:BEAMBeam Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/01/202422h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
08/01/202412h30GlobeNewswire Inc.Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
02/01/202412h30GlobeNewswire Inc.Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
14/12/202312h30GlobeNewswire Inc.Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsNASDAQ:BEAMBeam Therapeutics Inc
08/11/202312h30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
08/11/202312h30GlobeNewswire Inc.Beam Therapeutics to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
31/10/202311h59Dow Jones NewsBeam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million UpfrontNASDAQ:BEAMBeam Therapeutics Inc
31/10/202311h00GlobeNewswire Inc.Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular DiseaseNASDAQ:BEAMBeam Therapeutics Inc
25/10/202312h30GlobeNewswire Inc.Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCTNASDAQ:BEAMBeam Therapeutics Inc
19/10/202314h45GlobeNewswire Inc.Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines PipelineNASDAQ:BEAMBeam Therapeutics Inc
07/09/202316h00GlobeNewswire Inc.Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing MutationNASDAQ:BEAMBeam Therapeutics Inc
05/09/202312h30GlobeNewswire Inc.Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LLNASDAQ:BEAMBeam Therapeutics Inc
31/08/202312h30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
08/08/202312h30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
08/06/202322h56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BEAMBeam Therapeutics Inc
08/06/202322h32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BEAMBeam Therapeutics Inc
17/05/202312h30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming May Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
11/05/202312h30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM

Dernières Valeurs Consultées

LATK
XPATETH
BitNation Pangea Arbitration Tok
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés